Your session is about to expire
← Back to Search
Tafasitamab + Lenalidomide for Non-Hodgkin's Lymphoma (MINDway Trial)
MINDway Trial Summary
This trial is testing a new way to give the drug Tafasitamab to people with a certain type of lymphoma who have not responded to other treatments.
MINDway Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMINDway Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 81 Patients • NCT02399085MINDway Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer affects the central nervous system.I have had blood clots and cannot take medication to prevent them during treatment.I have had CD19 targeted therapy before and my lymphoma is still CD19 positive.I haven't had certain cancer treatments, major surgery, or live vaccines recently.I have had cancer before, but it has been in remission for over 2 years or was early-stage prostate cancer.I have a tumor visible on PET scan that is at least 1.5 cm by 1.0 cm.I agree to follow the study's rules on sex, contraception, and not donating eggs or sperm.My lymphoma is not the common type.I am 18 years old or older.I am able to understand and sign the consent form.I can take care of myself and am up and about more than half of my waking hours.I've had 1-3 treatments for DLBCL, including one targeting CD20.I have had 1-3 treatments for my refractory disease, including one targeting CD20.I have been treated with IMiDs before.I can provide tumor tissue samples for review.I do not have severe liver problems or jaundice, except if it's due to Gilbert's syndrome or lymphoma.I have HIV or have had an active HIV infection.I am still experiencing side effects from my previous treatments.My cancer has 'double/triple hit' genetic features.I had a stem cell transplant less than 3 months ago.My cancer has returned or is not responding to treatment.I have a rare hereditary sugar intolerance.I cannot take pills due to a stomach or intestine problem.I have had a stem cell transplant from a donor.My diagnosis is diffuse large B-cell lymphoma.
- Group 1: Treatment (Tafasitamab + Lenalidomide)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are new patients being accepted into this clinical trial?
"This study is still recruiting patients, as indicated by the clinicaltrials.gov website. This trial was first posted on July 19th, 2020 and updated last September 30th, 2020."
How can I sign up for the opportunity to participate in this research?
"This particular clinical trial is testing a new medication for patients with lymphoma, aged 18 to 80. Key inclusion criteria that participants must meet are as follows: having received no more than three previous systemic treatments for DLBCL, one of which must have included a CD20-targeted therapy; being in good general health according to the Eastern Cooperative Oncology Group scale; having measurable disease sites; and providing tumor tissue for central pathology review."
Does this research study allow people who are 35 years or older to participate?
"In order to participate in this particular clinical trial, patients must fall between the ages of 18-80. Out of the 1656 trials for patients over 65 and 308 trials for those under 18, this is one of the few that includes adults in this age bracket."
How many people can sign up for this clinical trial at most?
"In order for this study to happen, 51 individuals that fit the bill are required. The trial will be conducted by MorphoSys AG at various locations, two of which are Baptist Health in Lexington, Kentucky and Vista Oncology in Olympia, Washington."
What is the point of this research?
"The objectives of this study, which will take place over the course of 1 to 3 years, are to determine the recommended dosage and evaluate the pharmacokinetic profile. The secondary outcomes include assessing anti-tumor activity and duration of response."
Share this study with friends
Copy Link
Messenger